
News
Stay up to date. The MLL Munich Leukemia Laboratory stands for innovation and the best leukemia diagnostics. Here you will find the latest research and study results related to hematological diagnostics and the therapy based on them, as well as other exciting news and events.
The magazine
Dr. rer. nat. Sabine Riedel
at 26.03.2025
Looking Back at MLL Academy 2025
From March 24 to 26, the annual MLL Academy on "State of the art diagnostics in hematological malignancies" took place at the MLL in Munich. The event brought together nine international participants from Germany, Turkey, Canada, USA, Ukraine and the Netherlands. A varied program with theoretical and practical content as well as interactive discussions on the diagnosis of leukemia and lymphoma awaited them.
Prof. Dr. med. Dr. phil. Torsten Haferlach
at 19.12.2024
Growth, Progress, and Gratitude: 2024 Annual Review
The MLL MVZ reflects on a year filled with milestones: innovations in diagnostics, groundbreaking research, sustainable initiatives, and the expansion of international collaborations defined 2024. We continue to set standards in the service of patients. In our annual review, we present key facts and figures, new methods for diagnostics and personalized patient care, award-winning projects, the nationwide sample transport service, and other highlights from the year.
Julia Hennig
at 18.12.2024
KIM-Mail: A Secure Communication Channel for Medical Data
Every day, we are in close contact with colleagues, who are sending their patients sample to our laboratory. While much of this communication takes place by phone, we are also seeing a steady increase in written inquiries via e-mail. However, since standard e-mail is not suitable for exchanging sensitive patient data, and as part of our effort to replace outdated analog methods like faxing, we have introduced KIM-Mail as an additional option to the MLL portal for diagnostic reports.
PD Dr. med. Gregor Hörmann, PhD
at 18.12.2024
MLL’s new Sample Transport Service
An accurate and rapid diagnosis of leukemia and other hematological neoplasms is crucial for the best possible treatment of affected patients. In cooperation with our service partner Gold Key Services (GKS), we have established the nationwide sample transport service of the MLL Munich Leukemia Laboratory. Thanks to this service, samples can be delivered safely and reliably overnight to our laboratory in Munich. This also ensures that the test material arrives in optimal condition - for even more accurate diagnoses in the shortest possible time.
Vera Middelhauve
at 26.09.2024
Professional specialists, innovative measures and modern ways of securing young talent: Personnel work at MLL
In a company like MLL Munich Leukemia Laboratory, which is dedicated to the diagnosis, treatment and research of leukemia and lymphoma, responsible human resources management is of paramount importance: the Human Resources department ensures that highly qualified employees are not only recruited but also continuously developed to the highest standards. This is essential to achieve the best possible results for the satisfaction of our donors and the benefit of our patients.
Roman Möhlmann
at 28.06.2024
Recognition: Sixth consecutive TOP 100 award for the MLL
[Press release] Recognition at the German SME Summit - Ranga Yogeshwar honors MLL Munich Leukemia Laboratory for innovative achievements.
Dr. Dr. med. Armin Piehler, PhD MM
at 24.06.2025
MLL's new diagnostic service: UGT1A1 genotyping
Starting in July 2025, the MLL will offer UGT1A1 genotyping. This test will identify clinically relevant variants of this gene (28 and 6) to improve risk assessment for irinotecan or nilotinib therapy and diagnose Gilbert syndrome. This is a decisive step for personalized medicine and adapting therapy for drug-induced toxicity.
Dr. Dr. med. Armin Piehler, PhD MM
at 24.06.2025
Rapid Diagnosis of Rare Anemias: Novel WGS study launched at MLL
Congenital anemias are difficult to diagnose, especially when family history is unclear or laboratory values are ambiguous. In the new Genomnetzwerk Hämatologie study, "WGS in Hereditary Anemias," MLL uses whole genome sequencing (WGS) to help patients with suspected genetic anemia more quickly and effectively. Learn which criteria apply for study participation and how to register patients.
Dr. rer. nat. Katharina Hörst
at 23.06.2025
Molecular monitoring in AML: Not just prognostic, but predictive?
New Horizons in Leukemia Research: Focus on Selected Papers
In their study, Potter et al. investigated the potential benefits of monitoring measurable residual disease (MRD) sequentially in adults with acute myeloid leukemia (AML). The researchers aimed to determine whether adjusting therapy based on MRD results could improve patients' chances of survival. The results suggest that MRD monitoring may be especially beneficial for certain genetic subgroups.
Dr. Wencke Walter
at 25.03.2025
New Approaches in Diagnostics – Research and Innovation at MLL
To further support our ambitions and aspirations in these areas, two new departments were created at MLL in early 2025: "Research" and "Innovation". These teams are dedicated to the development of innovative diagnostic methods and applied hematology research to accelerate the translation of discoveries into practice.
Dr. rer. nat. Katharina Hörst
at 25.03.2025
New clonal cytopenia risk prediction score
New Horizons in Leukemia Research: Focus on Selected Papers
A recent study by Xie et al, published in Blood, presents a model to predict the progression of clonal cytopenia of undetermined significance (CCUS) to myeloid neoplasia (MN). The researchers developed the Clonal Cytopenia Risk Score (CCRS), which is based on three key factors. MLL Managing Director Prof. Dr. med. Torsten Haferlach commented on the study in Blood.
Dr. med. Christian Pohlkamp
at 25.03.2025
Rare diagnostics: examination methods outside the standard requirements
In addition to established standard tests, there are a number of diagnostic methods that are rarely requested but can still provide valuable information. These include genetic analyses of hereditary diseases, tests to determine resistance to targeted therapies, and specialized immunophenotyping techniques. This article presents some of these testing options, with the goal of maximizing the diagnostic options available to clients.
Roman Möhlmann
at 24.06.2025
Digitalization and Artificial Intelligence in Medicine: Seizing Opportunities and Taking Responsibility
Digitalization and artificial intelligence offer enormous opportunities for modern precision medicine, whether in cancer diagnostics or digital patient care. However, Germany's healthcare system is falling short of its potential. At MLL and MLL MVZ, we demonstrate what is needed now: clear decisions, bold pilot projects, and a new mindset for responsible healthcare tomorrow.
Dr. rer. nat. Isolde Summerer
at 06.10.2022
Chromosome Analysis 5.0 – Automation, Digitization and Artificial Intelligence
Chromosome analysis is an essential part of the diagnostics of malignant hematological diseases. It plays an important role in confirming the diagnostics, classification, prognosis assessment and therapy planning. The method is considered time-consuming and demanding, both laboratory-wise and in terms of evaluation and reporting. In addition to the continuous expansion of the automation of laboratory processes, the use of artificial intelligence (AI) in chromosome analysis in particular enables a significant reduction in the reporting time as well as a more objective and sensitive assessment of chromosomal changes.
Dr. rer. nat. Constanze Kühn
at 16.08.2021
MTLAs, doctors and artificial intelligence at MLL – a good team!
Dr. med. Christian Pohlkamp
at 06.08.2021
MLL and Institute of AI for Health of the Helmholtz Center of Munich Announce Research Collaboration
Prof. Dr. med. Dr. phil. Torsten Haferlach
at 30.09.2020
BELUGA - A Prospective, Registered Study on the Use of Artificial Intelligence (AI) in Hematology
at 18.02.2020
The Use of Artificial Intelligence at MLL Munich Leukemia Laboratory
Dr. Wencke Walter
at 24.01.2025
MLL Research Report 2024
This past year stands as a testament to our unwavering commitment. We've refined our diagnostic techniques and embraced cutting-edge technologies, all with the goal of unlocking deeper insights into blood diseases. Our belief remains firm: advancing medicine goes beyond merely assembling diverse expertise—it requires an insatiable thirst for knowledge. This report celebrates our journey toward that goal!
Dr. Wencke Walter
at 11.01.2024
Research Report 2023
This year was marked by various challenges, including war, natural disasters, and inflation, yet we managed to make significant strides in research. Our research report reflects the tireless dedication and innovative spirit of MLL's team as we continue to push the boundaries of knowledge in the field of hematology.
Dr. Wencke Walter
at 09.01.2023
Research Report 2022
Those who know us know that we always look ahead, push boundaries, and rarely stand still. We have reviewed the last scientific year and summarized our research highlights in the new Research Report 2022. Feel free to get caught up in our own passion and immerse yourself in our research with us. In 2022, we were once again energized, curious, and enthusiastic about advancing the best possible leukemia diagnostics for our patients. To further facilitate reading and to better convey our data, we have included various graphical representations and summaries and we hope you enjoy the content.
Dr. Wencke Walter
at 15.03.2022
Leukaemia diagnosis – Realising the potential of whole transcriptome sequencing
In AML and ALL the application of WHO classification and ELN guidelines requires a plethora of methods to determine the diagnostic and prognostic subgroup. Especially in ALL, many different subtypes have been described, which makes accurate diagnosis a challenge. However, in recent years, whole genome and whole transcriptome sequencing have emerged as comprehensive high-throughput techniques that allow for an accurate genetic characterization. This identification of patients’ genetic fingerprint is key to a precise diagnosis and the design of personalised cancer treatments.
Dr. Wencke Walter
at 28.12.2021
Research Report 2021
Dr. Wencke Walter
at 10.02.2020
Genomic & Transcriptomic Data Visualization
09.07.2025
Training event: The diagnostic view into the microscope
In our training event “The diagnostic look under the microscope - Hematology in the context of clinical, diagnostic and therapeutic aspects”, we would like to examine the influence of clinical and diagnostic aspects on treatment decisions together with you. Here you will find all information about the program and registration.
You may also be interested in
Your contact person

»Transparent communication both internally and externally is important to us.«
Roman Möhlmann